Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo.
Operator
Greetings and welcome to the MarineMax Fiscal First Quarter 2021 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Dawn Francfort, Head of Investor Relations. Please go ahead.
Dawn Francfort
Head of Investor Relations
Thank you, operator. Good morning everyone and thank you for joining this discussion of MarineMax fiscal first Quarter 2021 Conference Call. I m sure that you ve all received a copy of the press release that went out this morning, but if not, please call Linda Cameron at 727-531-1712, and she will email one to you right away.
And now, I would like to introduce the management team of MarineMax, Mr. Brett McGill, President and Chief Executive Officer and Mr. Mike McLamb, Chief Financial Officer of the Company. Management will make a few comments about the quarter and then be available for your questions. And with that in mind, let me turn the call over to Mike McLamb. Mike?
Operator
Greetings, and welcome to the Oshkosh Corporation Fiscal 2021 First Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Pat Davidson, Senior Vice President of Investor Relations for Oshkosh Corporation. Thank you, sir. You may begin.
Patrick Davidson
- Senior Vice President, Investor Relations
Good morning, and thanks for joining us. Earlier today, we published our first quarter 2021 results. A copy of the release is available on our website at oshkoshcorp.com. Today s call is being webcast and is accompanied by a slide presentation, which includes a reconciliation of GAAP to non-GAAP financial measures that we will use during this call and is also available on our website. The audio replay and slide presentation will be available on our website for approximately 12 months. So please refer now to slide two of that presentation. Our remarks should follow, including answ
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian® Linac
Second MRIdian System to be Installed at Henry Ford Health System s New Cancer Pavilion in Detroit
News provided by
Share this article
Share this article
CLEVELAND, Jan. 26, 2021 /PRNewswire/ ViewRay, Inc. (NASDAQ: VRAY) announced today that Henry Ford Cancer Institute has installed its second MRIdian Linac at its new cancer pavilion, Henry Ford Cancer Institute – Detroit, which began offering patient care on January 20, 2021.
Following FDA-clearance of the MRIdian Linac in February 2017, Henry Ford Cancer Institute became the first center in the world to install the next-generation system at one of its sites in Grosse Pointe Farms, Michigan. The MRIdian Linac was the first commercially available device to combine MRI-guidance with linear accelerator radiation delivery.
Operator
Good morning, and welcome to the Fourth Quarter Conference Call for Graco Inc. If you wish to access the replay for this call, you may do so by dialing 855-859-2056 within the United States or Canada. The dial-in number for international callers is 404-537-3406. The conference ID number is 5162659. The replay will be available through 2:00 PM Eastern Time, Tuesday, February 2, 2021. Graco has additional information available in the PowerPoint slide presentation, which is available as part of the webcast player. At the request of the company, we will open the conference up for questions and answers after the opening remarks from management. During this call, various remarks may be made by management about the expectations, plans and prospects for the future.